Every treatment plan is personalised. Dr Ashwin K.R. reviews your scans, pathology and, where relevant, biomarker results with a multidisciplinary team, then recommends a sequence of treatment that fits your cancer and your health.
Looking for more detail? Read our complete guide with 49 patient FAQs: Thoracic Cancer Treatment FAQs.
Common questions, answered
Lung and thoracic cancer questions answered →Lung cancer can be cured in many patients when it is found at an early stage, and even advanced lung cancer can now often be controlled for years with targeted therapy and immunotherapy.
Your chance of cure depends on:
What the evidence shows:
Thoracic cancer is any cancer that starts in the chest, including the lungs, the esophagus (food pipe), the pleura (lining of the lungs), the thymus, the trachea and the chest wall.
The main types of thoracic cancer are non-small cell lung cancer, small cell lung cancer, esophageal cancer, pleural mesothelioma and thymic tumors, with lung carcinoids and other rare tumors making up the rest.
Table 1. Types of thoracic cancer at a glance
| Type of Cancer | Where It Starts | Key Facts |
|---|---|---|
| Non-small cell lung cancer (NSCLC) | Lung tissue | About 85% of lung cancers; includes adenocarcinoma (most common, including in non-smokers), squamous cell and large cell carcinoma |
| Small cell lung cancer (SCLC) | Central airways of the lung | About 10–15% of lung cancers; grows quickly, strongly linked to smoking, often responds well to initial chemotherapy |
| Lung carcinoid (neuroendocrine) tumor | Hormone-producing cells of the airways | Usually slow-growing; frequently curable with surgery |
| Esophageal cancer | Food pipe | Squamous cell carcinoma is more common in Asia; adenocarcinoma is linked to chronic acid reflux and Barrett's esophagus |
| Pleural mesothelioma | Lining around the lungs | Strongly linked to past asbestos exposure, often decades earlier |
| Thymoma and thymic carcinoma | Thymus gland, behind the breastbone | Rare; thymoma may be associated with myasthenia gravis |
| Lung metastases | Cancer that has spread to the lungs from another organ | Treated according to the original (primary) cancer |
Lung cancer can develop in people who have never smoked; an estimated 10–25% of lung cancers worldwide occur in never-smokers, and the proportion is higher in parts of Asia.
Known causes in never-smokers include:
Why this matters:
Most patients begin thoracic cancer treatment within about two to six weeks of diagnosis, a timeframe generally considered appropriate for completing staging, biomarker testing and treatment planning.
Situations that may need urgent treatment:
Table 2. Typical timeline from diagnosis to treatment
| Step | What Happens | Typical Timeframe* |
|---|---|---|
| 1. First specialist consultation | History, examination, review of CT scans and reports | Within 1 week of referral |
| 2. Staging tests | PET-CT, brain MRI, lung function tests | 1–2 weeks |
| 3. Biopsy | Bronchoscopy, EBUS, CT-guided or endoscopic biopsy | Within 1–2 weeks |
| 4. Pathology and biomarkers | Cancer type, PD-L1, gene mutation testing | 3–7 working days (pathology); 1–3 weeks (genomics) |
| 5. Tumor board discussion | Multidisciplinary team recommends a plan | Within about 1 week of results |
| 6. Treatment begins | Surgery, radiation, chemotherapy, targeted therapy or immunotherapy | About 2–6 weeks from diagnosis |
*Timeframes vary with your cancer, test availability and personal circumstances.
A second opinion is a normal, widely accepted part of cancer care, and most oncologists welcome it.
A second opinion is especially useful when:
Bring these to your second-opinion appointment:
Five-year survival for thoracic cancer depends heavily on stage: it ranges from well over half of patients for early-stage non-small cell lung cancer to under 10% for many cancers that have spread to distant organs.
Table 3. Approximate five-year relative survival by stage
| Cancer Type | Localized | Regional (nearby spread) | Distant (spread far) | All Stages |
|---|---|---|---|---|
| Non-small cell lung cancer | ~65% | ~37% | ~9% | ~28% |
| Small cell lung cancer | ~30% | ~18% | ~3% | ~7% |
| Lung carcinoid tumor | ~97% | ~87% | ~58% | ~89% |
| Esophageal cancer | ~49% | ~28% | ~6% | ~22% |
| Pleural mesothelioma | ~18% | ~12% | ~10% | ~12% |
Source: rounded approximations of U.S. SEER / American Cancer Society five-year relative survival, for general education only. Your oncologist can explain your individual outlook.
Survival with stage 4 lung cancer has improved substantially, and many patients now live for several years, particularly those whose tumors have a targetable mutation or respond to immunotherapy.
Your oncologist can give you a more personal estimate based on your biomarkers, fitness and response to treatment.
Your stage describes the size of the tumor and how far it has spread, and it is one of the most important factors in choosing treatment and estimating prognosis.
Table 4. Lung cancer stages explained
| Stage | General Meaning | Typical Treatment Approach |
|---|---|---|
| Stage I | Small tumor confined to the lung, no lymph node spread | Surgery (lobectomy or segmentectomy) or SBRT if surgery is not suitable |
| Stage II | Larger tumor or spread to lymph nodes within the lung | Surgery with chemotherapy and/or immunotherapy before or after; targeted therapy after surgery for EGFR/ALK-positive tumors |
| Stage III | Spread to lymph nodes in the center of the chest (mediastinum) or tumor invading nearby structures | Chemoradiation followed by immunotherapy, or chemo-immunotherapy followed by surgery in selected patients |
| Stage IV | Spread to the other lung, fluid around the lung or heart, or distant organs (brain, bone, liver, adrenal) | Targeted therapy, immunotherapy and/or chemotherapy; radiation or surgery for selected sites |
Prognosis is shaped by the stage, type and biomarker profile of your cancer, your lung function and overall fitness, and how well the cancer responds to treatment.
Common warning signs of lung cancer include a cough that does not go away, coughing up blood, breathlessness, chest pain and unexplained weight loss; any of these lasting more than three weeks should be checked by a doctor.
Table 5. Common symptoms by thoracic cancer type
| Cancer Type | Common Symptoms |
|---|---|
| Lung cancer | Persistent or changing cough, coughing up blood, breathlessness, chest or shoulder pain, hoarseness, repeated chest infections, fatigue, weight loss, finger clubbing |
| Esophageal cancer | Difficulty swallowing (food sticking), pain on swallowing, unintentional weight loss, heartburn or indigestion that is new or persistent, vomiting, hoarseness |
| Pleural mesothelioma | Breathlessness from fluid around the lung, chest wall pain, fatigue, night sweats, weight loss |
| Thymic tumors | Chest pressure, cough, breathlessness; muscle weakness, drooping eyelids or double vision if linked with myasthenia gravis |
| Advanced spread | Bone pain, headaches or seizures, jaundice, swelling of the face and neck |
Early lung cancer often causes no symptoms. Many of these symptoms are more often caused by non-cancerous conditions, but they should still be assessed.
No, but coughing up blood (hemoptysis) is not considered normal and should be evaluated promptly, especially in current or former smokers over 40.
Lung cancer is often found late because the lungs have few pain nerves and early tumors rarely cause symptoms, so symptoms often appear only once the cancer has grown or spread.
Next step: if you are a current or former heavy smoker, ask your doctor whether you qualify for lung cancer screening.
See a doctor promptly for a cough lasting more than three weeks, coughing up blood, or difficulty swallowing, and seek emergency care for heavy bleeding, severe breathlessness or chest pain.
Table 6. How urgently to seek care
| Symptom | Action |
|---|---|
| Coughing up more than a few teaspoons of blood | Go to emergency care |
| Severe or sudden breathlessness, or chest pain | Go to emergency care |
| Swelling of the face, neck and arms with visible chest veins | Go to emergency care |
| New weakness or numbness in the legs, or loss of bladder control | Go to emergency care |
| Unable to swallow liquids or saliva | Seek same-day medical care |
| Any amount of blood in phlegm | Book a doctor's appointment within days |
| Cough, hoarseness or swallowing difficulty lasting more than 3 weeks | Book a doctor's appointment |
| Unexplained weight loss | Book a doctor's appointment |
Thoracic cancer is confirmed by examining a tissue or fluid sample under the microscope, and scans, endoscopy and lung function tests are used to determine the stage and plan treatment.
Table 7. Diagnostic and staging tests for thoracic cancer
| Test | Purpose |
|---|---|
| Chest X-ray | Often the first test; may show a mass or fluid |
| Contrast CT scan of chest and abdomen | Shows tumor size, lymph nodes and spread to the liver or adrenal glands |
| PET-CT scan | Detects active cancer in lymph nodes, bones and other organs; key for staging before surgery or radiation |
| MRI brain | Checks for brain metastases, which may not cause symptoms |
| Bronchoscopy (including navigational / robotic bronchoscopy) | Camera into the airways to inspect and take biopsies |
| EBUS-TBNA (endobronchial ultrasound) | Samples lymph nodes in the center of the chest through the airway, without surgery |
| CT-guided needle biopsy | Samples a lung nodule through the chest wall |
| Upper GI endoscopy and endoscopic ultrasound (EUS) | Diagnoses and stages esophageal cancer |
| Pleural tap (thoracentesis) or thoracoscopy | Samples fluid or lining of the lung; key for mesothelioma |
| Pulmonary function tests and cardiac tests | Help estimate whether surgery or radiation is likely to be well tolerated |
| Molecular and PD-L1 testing | Identifies targeted therapy and immunotherapy options |
Lung biopsies are generally well tolerated, and the risk of a biopsy spreading cancer is very low; the information gained is needed to choose the right treatment.
Table 8. What to expect on the day of a biopsy
| Procedure | Anesthesia | Procedure Time | Fasting* | Usually Home |
|---|---|---|---|---|
| CT-guided lung biopsy | Local anesthetic ± mild sedation | 30–60 minutes | 4–6 hours | Same day, after 2–4 hours' observation and a chest X-ray |
| Bronchoscopy / EBUS-TBNA | Sedation or general anesthesia | 30–60 minutes | 6 hours | Same day |
| Navigational / robotic bronchoscopy | General anesthesia | 45–90 minutes | 6 hours | Same day |
| Upper GI endoscopy / EUS | Sedation | 15–45 minutes | 6 hours | Same day |
| Pleural tap (thoracentesis) | Local anesthetic | 15–30 minutes | Usually none | Same day |
| Medical thoracoscopy / VATS biopsy | Sedation or general anesthesia | 30–60 minutes | 6 hours | 1–3 days (chest drain) |
*Follow the exact fasting and blood-thinner instructions given by your team. A responsible adult should take you home after sedation.
Biomarker (molecular) testing looks for specific gene changes and proteins in lung cancer, and international guidelines recommend it for advanced non-small cell lung cancer because it can identify targeted tablets or immunotherapy that may work better than chemotherapy alone.
Table 9. Key biomarkers in non-small cell lung cancer
| Biomarker | How Common (approx.) | Examples of Matched Treatment |
|---|---|---|
| EGFR mutation | About 10–15% in Western patients; considerably higher (up to around 30–50%) in Asian patients and never-smokers with adenocarcinoma | Osimertinib; amivantamab-based combinations |
| ALK rearrangement | About 3–7%, more often in younger never-smokers | Alectinib, lorlatinib, brigatinib |
| ROS1 rearrangement | About 1–2% | Crizotinib, entrectinib, repotrectinib |
| KRAS G12C mutation | About 10–13% of adenocarcinomas, mainly in smokers | Sotorasib, adagrasib |
| BRAF V600E mutation | About 1–2% | Dabrafenib + trametinib |
| MET exon 14 skipping | About 3–4% | Capmatinib, tepotinib |
| RET fusion | About 1–2% | Selpercatinib, pralsetinib |
| HER2 mutation | About 2–4% | Trastuzumab deruxtecan |
| NTRK fusion | Under 1% | Larotrectinib, entrectinib |
| PD-L1 expression | Varies; about 30% have high (≥50%) expression | Guides immunotherapy choice |
Most biopsy results are available within about 3 to 7 working days, while comprehensive gene testing (next-generation sequencing) usually takes 1 to 3 weeks.
Table 10. Typical test result turnaround times
| Test | Typical Turnaround* | Can Treatment Start Before Results? |
|---|---|---|
| CT / PET-CT / MRI report | Same day to 2 days | Not applicable |
| Biopsy (histopathology) | 3–7 working days | No – diagnosis must be confirmed first |
| PD-L1 (immunohistochemistry) | 3–7 working days | Usually waited for in advanced NSCLC |
| Single-gene tests (EGFR PCR, ALK IHC) | 3–7 working days | Usually waited for in advanced NSCLC |
| Next-generation sequencing (NGS) on tissue | 1–3 weeks | Often waited for unless symptoms are urgent |
| Liquid biopsy (blood NGS) | About 1–2 weeks | Can run in parallel with tissue testing |
*Turnaround times vary between laboratories.
The most suitable treatment depends on the type, stage and biomarker profile of your cancer and your fitness, and it is recommended by a multidisciplinary thoracic tumor board.
Table 11. Main treatments by thoracic cancer type and stage
| Cancer Type | Early / Localized | Locally Advanced | Metastatic |
|---|---|---|---|
| NSCLC | Lobectomy or segmentectomy; SBRT if not fit for surgery | Chemo-immunotherapy then surgery, or chemoradiation then durvalumab | Targeted therapy if a driver mutation is found; otherwise immunotherapy ± chemotherapy |
| SCLC | Surgery for very small tumors (rare), then chemotherapy | Chemotherapy with concurrent radiation (limited stage) | Chemotherapy plus immunotherapy (extensive stage) |
| Lung carcinoid | Surgery | Surgery with lymph node removal | Somatostatin analogues, targeted therapy, PRRT |
| Esophageal cancer | Endoscopic resection for very early tumors; esophagectomy | Chemoradiation or perioperative chemotherapy, then esophagectomy; definitive chemoradiation for some | Chemotherapy with immunotherapy and/or HER2-targeted therapy |
| Pleural mesothelioma | Surgery (pleurectomy/decortication) within multimodality treatment in selected patients | Immunotherapy or chemotherapy ± surgery | Nivolumab + ipilimumab, or chemotherapy ± immunotherapy |
| Thymoma / thymic carcinoma | Thymectomy | Surgery ± radiation; chemotherapy to shrink first if needed | Chemotherapy; targeted therapy in selected cases |
Table 12. How long does lung cancer treatment take? Typical pathways
| Treatment Pathway | Active Treatment Phase | Additional / Maintenance Phase | Approximate Total Duration* |
|---|---|---|---|
| Stage I – surgery | Surgery with 2–4 day hospital stay | None for most patients | About 1–2 months including recovery |
| Stage I – SBRT | 1–8 sessions over 1–2 weeks | None | About 2 weeks |
| Stage II–III – chemo-immunotherapy, then surgery | 3–4 cycles over 9–12 weeks, then surgery | Immunotherapy after surgery in some patients, up to about 1 year | About 4–15 months |
| Stage II–III EGFR-positive – surgery, then targeted therapy | Surgery ± chemotherapy (about 3 months) | Osimertinib tablets for 3 years | About 3–3½ years |
| Stage III – chemoradiation | Daily radiation with chemotherapy over about 6 weeks | Durvalumab every 2–4 weeks for up to 12 months | About 13–14 months |
| Stage IV – targeted therapy | Daily tablets | Continued while effective and tolerated | Ongoing |
| Stage IV – chemo-immunotherapy | 4 cycles over about 12 weeks | Maintenance immunotherapy ± pemetrexed, up to about 2 years | Up to about 2 years |
*Durations are typical examples from current standard pathways and vary with response, side effects and individual plans.
Surgery offers one of the best chances of cure for many early-stage lung cancers and is usually recommended when the tumor can be fully removed and your lung function allows it.
Table 13. Types of thoracic cancer surgery
| Procedure | What Is Removed | Commonly Used For |
|---|---|---|
| Lobectomy | One lobe of the lung (the right lung has 3, the left has 2) | Standard operation for most early NSCLC |
| Segmentectomy | One or more anatomical segments of a lobe | Small (about 2 cm or less) peripheral tumors; patients with limited lung function |
| Wedge resection | A small wedge of lung around the tumor | Small nodules, carcinoids, metastases, or patients unfit for larger surgery |
| Sleeve lobectomy | A lobe plus a section of airway, which is rejoined | Central tumors, to avoid removing the whole lung |
| Pneumonectomy | The entire lung | Large central tumors when lesser surgery is not possible |
| Esophagectomy | Part of the esophagus, reconstructed using the stomach | Esophageal cancer |
| Thymectomy | The thymus gland and surrounding fat | Thymoma and thymic carcinoma |
| Pleurectomy / decortication | The lining of the lung and chest wall | Selected pleural mesothelioma |
Table 14. Preparing for lung cancer surgery: timeline checklist
| When | What to Do* |
|---|---|
| As soon as surgery is planned | Stop smoking; start walking and breathing exercises (prehabilitation); ask about pulmonary rehabilitation |
| 2–3 weeks before | Pre-operative assessment: blood tests, ECG, lung function tests; review of all medicines |
| About 5–7 days before | Stop or adjust blood thinners and certain diabetes or herbal medicines – only as instructed by your team |
| Night before | Fast as instructed (usually no food for 6 hours and clear fluids until 2 hours before) |
| Day of surgery | Bring your medicines list, reports and comfortable clothing; arrange someone to take you home on discharge |
*Always follow your own surgical team's instructions, which may differ.
Robotic-assisted and VATS (video-assisted thoracoscopic) surgery are now widely used for most early-stage lung cancer operations, offering faster recovery with cancer outcomes comparable to open surgery in large studies.
Potential benefits:
Note: Some large or central tumors, or tumors invading the chest wall or major vessels, may still require open surgery. Your surgeon will advise the most suitable approach.
Many people live active, independent lives after lung cancer surgery, because the remaining lung tissue usually provides enough breathing capacity for everyday activities.
Table 15. Typical hospital stay and recovery after thoracic surgery
| Surgery | Hospital Stay* | Light Activity | Return to Desk Work* | Driving* |
|---|---|---|---|---|
| Robotic / VATS lobectomy or segmentectomy | 2–4 days | Within 1 week | 3–6 weeks | About 2–4 weeks |
| Open lobectomy (thoracotomy) | 4–7 days | 1–2 weeks | 6–12 weeks | 4–6 weeks |
| Pneumonectomy | 5–10 days | 2–3 weeks | 2–3 months | 4–6 weeks |
| Esophagectomy | 7–14 days | 2–4 weeks | 2–3 months | 4–8 weeks |
| Robotic / VATS thymectomy | 1–3 days | Within 1 week | 2–4 weeks | About 2 weeks |
*Recovery varies with the extent of surgery, your fitness and any complications. Drive only when you can turn and brake comfortably and are not taking sedating pain medication.
Table 16. Typical recovery milestones after robotic / VATS lung surgery
| Milestone | Typical Timing* |
|---|---|
| Sitting out of bed and walking | Day of surgery or day 1 |
| Chest drain removed | Day 1–3 (later if there is an air leak) |
| Discharge home | Day 2–4 |
| Wound check and pathology results | 1–2 weeks after surgery |
| Avoid heavy lifting (over about 5 kg) | 4–6 weeks |
| Start of additional treatment (if needed) | Usually 4–8 weeks after surgery |
| Near-normal energy levels | 1–3 months |
*Milestones vary between individuals.
SBRT (stereotactic body radiotherapy) delivers very precise, high-dose radiation in a few sessions and is a standard, effective treatment for early-stage lung cancer in people who cannot have or do not want surgery.
Radiation therapy is used with curative intent for early lung cancer, to treat locally advanced lung and esophageal cancer together with chemotherapy, and to relieve symptoms when cancer has spread.
Table 17. Radiation treatment types and schedules
| Type | Used For | Typical Schedule |
|---|---|---|
| SBRT / SABR | Early lung cancer; limited metastases | 1–8 sessions over 1–2 weeks |
| Chemoradiation (IMRT / VMAT / IGRT) | Stage III NSCLC; limited-stage SCLC; esophageal cancer | About 25–33 daily sessions, 5 days a week, over 5–6½ weeks |
| Pre-operative chemoradiation | Esophageal cancer before esophagectomy | About 23 sessions over 5 weeks, with weekly chemotherapy |
| Stereotactic radiosurgery (SRS) | Small brain metastases | 1–5 sessions |
| Palliative radiation | Bone pain, bleeding, airway blockage | 1–10 sessions |
| Proton therapy (selected centers) | Selected cases where sparing the heart or lungs is critical | Similar to conventional schedules |
Chemotherapy is used for many thoracic cancers – before or after surgery, together with radiation, or in combination with immunotherapy for advanced disease – and is usually given as day-care infusions every three weeks.
Table 18. Common systemic treatment schedules at a glance
| Treatment | Used For | How Often | Typical Course | Setting / Time per Visit |
|---|---|---|---|---|
| Platinum doublet chemotherapy (e.g. carboplatin/cisplatin + pemetrexed or paclitaxel) | NSCLC, mesothelioma | Every 3 weeks | 4 cycles (about 12 weeks), sometimes followed by maintenance | Day care; about 3–5 hours |
| Carboplatin/cisplatin + etoposide + immunotherapy | Extensive-stage SCLC | Every 3 weeks | 4 cycles, then immunotherapy maintenance | Day care; 3 consecutive days of etoposide |
| Chemo-immunotherapy before surgery | Stage II–III NSCLC | Every 3 weeks | 3–4 cycles before surgery | Day care; about 3–5 hours |
| Weekly carboplatin + paclitaxel with radiation | Esophageal cancer | Weekly | 5 weeks | Day care; about 2–3 hours |
| FLOT chemotherapy | Esophageal / GE junction adenocarcinoma | Every 2 weeks | 4 cycles before and 4 after surgery | Day care with 24-hour infusion pump at home |
| Immunotherapy alone (pembrolizumab, nivolumab, atezolizumab, durvalumab) | NSCLC, SCLC, esophageal cancer, mesothelioma | Every 2–6 weeks | Up to about 1–2 years, depending on setting | Day care; about 30–60 minutes |
| Targeted tablets (e.g. osimertinib, alectinib) | Biomarker-positive NSCLC | Daily at home | As long as effective in advanced disease; 3 years after surgery for some | Monthly or quarterly review |
Schedules are typical examples. Your regimen may differ based on your cancer, blood counts and tolerance.
Targeted therapy uses drugs, usually daily tablets, that block a specific gene change driving the cancer; for patients whose tumors carry that change, trials have shown it is often more effective and better tolerated than chemotherapy.
Immunotherapy is a standard treatment for many lung cancers, esophageal cancers and mesotheliomas, and in a proportion of patients it produces responses that last for years.
Esophageal cancer is usually treated with chemotherapy or chemoradiation followed by surgery when the cancer is localized, while very early tumors may be removed endoscopically and advanced cancers are treated with systemic therapy.
Table 19. Typical esophageal cancer treatment timeline (localized disease)
| Phase | What Happens | Typical Duration* |
|---|---|---|
| Staging and planning | Endoscopy, EUS, PET-CT, nutrition assessment, tumor board | 2–4 weeks |
| Pre-operative treatment | Chemoradiation (about 5 weeks) or FLOT chemotherapy (4 cycles, about 8 weeks) | 5–8 weeks |
| Recovery and re-staging | Rest, nutrition support, repeat PET-CT | About 6–10 weeks |
| Esophagectomy | Surgery and hospital stay | 7–14 days in hospital |
| Post-operative treatment | Immunotherapy (nivolumab) for residual disease, or 4 further FLOT cycles | About 2 months to 1 year |
| Full recovery of eating and energy | Small frequent meals, dietitian follow-up | 3–6 months or longer |
*Typical examples; your pathway may differ.
Pleural mesothelioma is usually treated with immunotherapy or chemotherapy, with surgery and radiation offered to carefully selected patients as part of a multimodality plan at specialist centers.
A thoracic tumor board is a meeting where specialists from each relevant field review your case together to agree on a recommended treatment plan.
Clinical trials offer access to promising new treatments and may be a suitable option at many stages of thoracic cancer.
Side effects depend on the treatment you receive; many are temporary, and most can be reduced with modern supportive care.
Table 20. Common side effects and how they are managed
| Treatment | Common Side Effects | How They Are Managed |
|---|---|---|
| Lung surgery | Pain, breathlessness, air leak, chest infection, fatigue, numbness around the scar | Pain relief, breathing exercises, early walking, physiotherapy |
| Esophagectomy | Difficulty eating large meals, reflux, weight loss, dumping syndrome | Small frequent meals, dietitian support, sleeping propped up |
| Chemotherapy | Fatigue, nausea, low blood counts and infection risk, hair loss (with some drugs), neuropathy | Anti-nausea medicines, growth factor injections, dose adjustments |
| Chest radiation | Fatigue, painful swallowing (esophagitis), skin redness, cough | Pain relief, soft diet, skin care |
| Radiation pneumonitis (weeks to months later) | Cough, breathlessness, low fever | Steroids; early reporting is important |
| Targeted therapy | Skin rash, diarrhea, nail infections, liver changes, swelling | Skin care, antidiarrheals, dose adjustment |
| Immunotherapy | Fatigue, rash, thyroid problems, colitis, pneumonitis, hepatitis | Early reporting, steroids or hormone replacement as needed |
Hair loss depends on the drugs used: paclitaxel and etoposide commonly cause hair loss, while pemetrexed, carboplatin alone, immunotherapy and most targeted tablets usually do not.
Breathlessness, cough and fatigue are common with thoracic cancer, and each can often be eased with a combination of medical treatment and practical self-care.
Table 21. Options for draining fluid around the lung (pleural effusion)
| Procedure | What It Involves | Hospital Stay* | Best Suited For |
|---|---|---|---|
| Pleural tap (thoracentesis) | Needle drainage of fluid under local anesthetic | Same day | Quick relief; fluid may return |
| Indwelling pleural catheter (IPC) | Thin tube left in place; fluid drained at home, often 2–3 times a week | Day procedure | Recurrent fluid; avoiding hospital stays |
| Talc pleurodesis | Talc used to seal the space around the lung, via chest drain or thoracoscopy | About 2–5 days | Recurrent fluid when the lung fully re-expands |
*Stays vary with your condition.
Contact your oncology team immediately, day or night, if you develop a temperature of 38°C (100.4°F) or above during chemotherapy, or sudden worsening of breathing.
Table 22. When to contact your care team
| Symptom | Threshold | Action |
|---|---|---|
| Fever or chills | 38.0°C (100.4°F) or above, or shivering | Call immediately / go to emergency |
| Breathlessness | Sudden or rapidly worsening, or at rest | Go to emergency care |
| Coughing up blood | More than a few teaspoons | Go to emergency care |
| Chest pain | New, severe or with breathlessness | Go to emergency care |
| New cough with fever on immunotherapy or after radiation | Any | Call the same day (possible pneumonitis) |
| Diarrhea | More than 4–6 episodes a day above normal, or bloody | Call the same day |
| Unable to swallow fluids | For 12–24 hours | Call the same day |
| Leg pain or swelling | One leg red, painful or swollen | Call the same day (possible blood clot) |
| Confusion, severe headache, seizure or new weakness | Any new episode | Go to emergency care |
Follow any specific thresholds your own team gives you. +91 88840 09955
Yes. Stopping smoking after a lung cancer diagnosis is one of the most beneficial steps you can take, and quitting is worthwhile at any stage of treatment.
Table 23. Stop-smoking support options
| Option | How It Is Used | Typical Duration* |
|---|---|---|
| Nicotine replacement (patch, gum, lozenge) | Patch for steady levels plus a fast-acting form for cravings | 8–12 weeks |
| Varenicline (prescription tablet) | Start 1–2 weeks before your quit date | 12 weeks, sometimes longer |
| Bupropion (prescription tablet) | Start 1–2 weeks before your quit date | 7–12 weeks |
| Counselling / quitline support | Individual, group or telephone sessions | Several sessions over weeks to months |
*Your doctor will check which options are suitable alongside your cancer treatment.
Most people are encouraged to stay physically active during and after thoracic cancer treatment, adjusting intensity to how they feel and to their team's advice.
Maintaining nutrition is very important during thoracic cancer treatment, and a cancer dietitian can tailor a plan when swallowing is difficult or weight is falling.
Many patients can travel during thoracic cancer treatment, but flying soon after lung surgery or with low oxygen levels requires medical clearance.
Smoking is the leading cause of lung cancer, but radon, air pollution, asbestos and other exposures, as well as inherited and acquired gene changes, also contribute.
Table 24. Main risk factors by thoracic cancer type
| Cancer Type | Main Risk Factors |
|---|---|
| Lung cancer | Tobacco smoking (including bidis and second-hand smoke), radon, air pollution, indoor biomass smoke, asbestos, silica, previous chest radiation, family history, prior tuberculosis or lung scarring |
| Esophageal squamous cell carcinoma | Tobacco (smoked and chewed), alcohol, very hot beverages, nutritional deficiencies |
| Esophageal adenocarcinoma | Chronic acid reflux (GERD), Barrett's esophagus, obesity, smoking |
| Pleural mesothelioma | Asbestos exposure, often 20–50 years before diagnosis; prior radiation; rarely inherited BAP1 mutation |
| Thymic tumors | No clear lifestyle cause identified |
Most lung cancers are not inherited, but having a close relative with lung cancer modestly increases risk, and a small number of thoracic cancers are linked to inherited gene mutations.
Annual low-dose CT (LDCT) screening is recommended for people at high risk of lung cancer, and in large trials it reduced lung cancer deaths by around 20–24%.
Table 25. Lung cancer screening eligibility (U.S. USPSTF guidance)
| Criterion | Recommendation |
|---|---|
| Age | 50–80 years |
| Smoking history | At least 20 pack-years (e.g. 1 pack a day for 20 years) |
| Smoking status | Currently smoking or quit within the past 15 years |
| Test | Low-dose CT scan of the chest, once a year |
| Scan time | Under 1 minute of scanning; no injection needed |
Table 26. Understanding your screening CT result (Lung-RADS categories)
| Category | What It Means | Typical Next Step* |
|---|---|---|
| 1 – Negative | No nodules or definitely benign findings | Repeat low-dose CT in 12 months |
| 2 – Benign appearance | Nodules very unlikely to be cancer | Repeat low-dose CT in 12 months |
| 3 – Probably benign | Low likelihood of cancer | Low-dose CT in 6 months |
| 4A – Suspicious | Moderate likelihood of cancer | Low-dose CT in 3 months; PET-CT may be considered |
| 4B / 4X – Very suspicious | Higher likelihood of cancer | Diagnostic CT, PET-CT and/or biopsy, with specialist referral |
*Based on the American College of Radiology Lung-RADS system; your doctor will tailor follow-up to your scan.
The risk of recurrence depends on stage and type: it is lower for stage I cancers and higher for stage II–III and small cell lung cancer, which is why regular follow-up scans are important.
Follow-up care involves regular check-ups and chest CT scans, most frequently in the first two to three years after treatment when recurrence risk is highest.
Table 27. Typical follow-up schedule after curative treatment
| Time Since Treatment | Typical Visit Frequency | What Is Checked |
|---|---|---|
| Years 1–2 | Every 3–6 months | Symptoms, examination, chest CT scan, side effect management |
| Year 3 | Every 6 months | Examination and chest CT scan |
| Years 4–5 | Every 6–12 months | Examination and chest CT scan |
| After 5 years | Once a year | Low-dose chest CT, smoking cessation support, survivorship care |
Recurrent or metastatic lung cancer can often still be treated, and many patients have several lines of effective therapy available.
Feeling shocked, frightened, angry or guilty after a thoracic cancer diagnosis is common and understandable, and professional emotional support is an important part of cancer care.
Many people continue working during treatment, often with adjusted hours or duties, although most need time off after surgery.
Table 28. Planning work around treatment
| Treatment Phase | Typical Impact on Work* |
|---|---|
| Robotic / VATS lung surgery | 3–6 weeks off |
| Open lung surgery or esophagectomy | 6 weeks to 3 months off |
| Chemotherapy every 3 weeks | Often most tired for 3–7 days after each cycle; many work part-time |
| Daily chemoradiation (5–6 weeks) | Daily visits; fatigue and swallowing discomfort build toward the end – many take time off |
| SBRT (1–8 sessions) | Usually minimal time off |
| Targeted tablets or immunotherapy | Most people can work normally |
*Individual experiences vary.
The cost of thoracic cancer treatment varies widely with the type of surgery, radiation and drugs used, and many health insurance plans cover a large part of it.
Table 29. Cost estimate overview (to be completed by hospital)
| Treatment | Estimated Cost Range | Typically Covered by Insurance? |
|---|---|---|
| Robotic / VATS lobectomy | [range] | [Yes / Partial] |
| Esophagectomy | [range] | [ ] |
| SBRT (full course) | [range] | [ ] |
| Chemoradiation (full course) | [range] | [ ] |
| Chemotherapy (per cycle) | [range] | [ ] |
| Targeted therapy / immunotherapy (per month) | [range] | [ ] |
Preparing a list of questions before your first appointment helps you understand your diagnosis and take an active part in treatment decisions.
Table 30. What to bring to your first appointment
| Item | Why It Helps |
|---|---|
| Referral letter and prior consultation notes | Gives the team your full history |
| CT / PET-CT / MRI images (CD or link) and reports | Avoids unnecessary repeat scans |
| Pathology report and biopsy blocks / slides | Allows review and additional biomarker testing |
| Biomarker and PD-L1 reports | Guides treatment choice |
| Lung function tests and recent blood results | Helps assess fitness for treatment |
| List of current medicines, inhalers and allergies | Helps your team avoid drug interactions and allergic reactions |
| Insurance card and ID | Speeds up registration and pre-authorisation |
| A family member or friend | Helps with listening, notes and support |
At Aster Whitefield Hospital, patients with lung, esophageal and other chest cancers can access:
Book a consultation with a thoracic oncology specialist. Call +91 88840 09955 or /contact/ to schedule an appointment or request a second opinion.
Medical disclaimer – please note:
Medically reviewed by Dr Ashwin K.R. · Last reviewed: 10 October 2026
Medical disclaimer: This information is for general education and does not replace personalised medical advice. Please consult a qualified doctor about your specific diagnosis and treatment.